as reported by PMLive.com Venture Capitalist company, Third Rock Ventures has expanded by hired some of the industries top professionals. Having appointed executives from Lilly, Genzyme, Alnylam and InClone the company, which helps build healthcare companies plans to use the new expertise to translate scientific innovations into new companies.
James Geraghty, who has spent 20-years at Genzyme, becomes entrepreneur-in-residence, while
Steven Paul the former president of Lilly Research Laboratories, takes on an increased role at Third Rock with a position as a venture partner.
Daniel Lynch, former CEO of ImClone Systems and John Maraganore, Alnylam’s CEO are also joining as venture partners.
Robert Tepper, partner at Third Rock Ventures, said: “These leaders have demonstrated – through decades of experience – their ability to integrate science and business.
“The depth of their expertise across commercial, business development, R&D, drug discovery and product development will be invaluable to Third Rock as we focus on translating scientific innovation into exceptional companies that make a difference for patients.”